PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
| Title: | PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma |
|---|---|
| Authors: | Dagmar Kollmann, Desislava Ignatova, Julia Jedamzik, Yun-Tsan Chang, Gerd Jomrich, Andreas Baierl, Dmitry Kazakov, Michal Michal, Lars E. French, Wolfram Hoetzenecker, Tobias Schatton, Reza Asari, Matthias Preusser, Michael Gnant, Emmanuella Guenova, Sebastian F. Schoppmann |
| Source: | OncoImmunology, Vol 7, Iss 6 (2018) |
| Publisher Information: | Taylor & Francis Group, 2018. |
| Publication Year: | 2018 |
| Collection: | LCC:Immunologic diseases. Allergy LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | pd-1, pd-l1, pd-l2, esophageal adenocarcinoma, esophageal carcinoma, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Background. The outcome of patients with adenocarcinoma of the esophagogastric junction (AEG) remains poor. The programmed cell-death-protein-1 (PD-1), a co-inhibitory receptor primarily expressed by T-cells, represents a potential new therapeutic target. PD-1, PD-1 ligand 1 (PD-L1), and PD-L2 expression have all been described as prognostic factors in a variety of cancers. Their expression patterns in AEG, however, are poorly understood. We analyzed PD-L1, PD-L2 and PD-1 expression by tumor-infiltrating lymphocytes (TILs) and cancer-cells in tumor-biospecimens in AEG-patients. Methods. 168 patients who underwent esophagectomy because of AEG between 1992–2011 were included in this study. PD-L1, PD-L2 and PD-1 expression were evaluated by immunohistochemistry and correlated with various clinicopathological parameters, disease-free survival (DFS) and long-term overall survival (OS). Results. PD-L1 expression by cancer-cells (cancer-cell-PD-L1+) was found in 43.5% of patients whereas PD-L1 expression by TILs (TILs-PD-L1+) was observed in 69%. PD-L2 expression by cancer-cells and TILs was only found in 3.5% and 1.8%, respectively. Additionally, 77.4% of tumors contained PD-1+-cancer-cells and 81% PD-1+-TILs. Patients with increased expression of PD-1 by cancer-cells and TILs showed significantly reduced OS and DFS, as determined by univariate, but not multivariate analysis. Expression of PD-L1 by cancer-cells was found to be an independent predictor for improved DFS (p = 0.038) and OS (p = 0.042) in multivariate analysis. Conclusions. Cancer cells and TILs displayed PD-L1 expression in around 50% and PD-1 expression in around 80% of tumor-biospecimens obtained from AEG patients. Expression of PD-L1 is an independent predictor of favorable outcome in AEG, whereas PD-1 expression is associated with worse outcome and advanced tumor stage. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2162-402X 2162402X 80448968 |
| Relation: | https://doaj.org/toc/2162-402X |
| DOI: | 10.1080/2162402X.2018.1435226 |
| Access URL: | https://doaj.org/article/68247f40b804489683c749b0f2a3c84a |
| Accession Number: | edsdoj.68247f40b804489683c749b0f2a3c84a |
| Database: | Directory of Open Access Journals |
| ISSN: | 2162402X 80448968 |
|---|---|
| DOI: | 10.1080/2162402X.2018.1435226 |
| Published in: | OncoImmunology |
| Language: | English |